MyHealthChecked PLC - Cardiff-based healthcare company - Posts revenue of £22.3 million for 2022, up 36% from £16.4 million in 2021. Says the increase is due to the significant demand from top high street pharmacy retailers for Covid lateral flow tests. Pretax profit, however, falls 25% to £1.5 million from £2.0 million, as sales & marketing costs rise to £798,000 from £699,000 a year earlier. Says the rise in costs is due to the ‘increased investment in marketing activities associated with the new and planned product launches’. Incurs an additional consideration of £987,000 payable on the acquisition of The Genome Store Ltd, compared to none in 2021. Looking ahead, sees steady sales in 2023, and is ready to respond to spikes in demand as the year progresses.
Chief Executive Officer Penny McCormick says: ‘MHC has not only established itself as a player in the wellness industry but has also achieved excellent financial results in the last two years. Our commitment to innovation, customer satisfaction, and financial stability and management has set us on a path to delivering our goal of sustained liquidity.’
Current stock price: 0.99 pence each, down 5.8% on Monday morning in London
12-month change: down 53%
Copyright 2023 Alliance News Ltd. All Rights Reserved.
